Search results for "drug interactions"

showing 10 items of 229 documents

Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole

2003

Managing invasive fungal infections often presents a challenge for clinicians in the treatment of immunocompromised patients. Two very different systemic antifungal agents, voriconazole and caspofungin, have recently been introduced into the market place. Voriconazole is a new triazole antifungal, while caspofungin is the first echinocandin antifungal. Voriconazole acts by inhibiting the synthesis of ergosterol in the fungal cell membrane. Caspofungin inhibits beta-1,3-D-glucan synthesis in the cell wall, a target present in fungal cells, but absent from mammalian cells. Both agents are broad-spectrum, with efficacy against invasive Aspergillus and Candida infections. The safety and tolerab…

DrugAntifungal AgentsEchinocandinmedia_common.quotation_subjectPharmacologyPeptides CyclicEchinocandinsLipopeptideschemistry.chemical_compoundCaspofunginpolycyclic compoundsmedicineAspergillosisHumansDrug InteractionsAdverse effectmedia_commonVoriconazoleClinical Trials as Topicbusiness.industryCandidiasisGeneral MedicineTriazolesDrug interactionClinical trialPyrimidinesTreatment OutcomeTolerabilitychemistryVoriconazoleCaspofunginPeptidesbusinessmedicine.drugCurrent Medical Research and Opinion
researchProduct

Biochemical approach on the conservation of drug molecules during hair fiber formation

1997

A biochemical concept for the endogenous incorporation of drug molecules into growing hair is presented. It is based on the principles of transport across biomembranes, on the principles of biotransformation and drug melanin affinity. The approach gives explanations for current observations in hair analysis, which up to date have not been understood sufficiently. Phenomena such as the ratio of parent drug to metabolite in hair, the dependence of incorporation on the physico-chemical properties of the drug, the independence of drug incorporation on active melanogenesis (incorporation into non-pigmented hair) as well as the dependence of drug content on hair pigmentation are elucidated.

DrugCell Membrane PermeabilityMembrane permeabilitymedia_common.quotation_subjectMetaboliteBiologyAbsorptionPathology and Forensic MedicineMelaninStructure-Activity Relationshipchemistry.chemical_compoundBiotransformationKeratinotorhinolaryngologic diseasesmedicineAnimalsHumansDrug InteractionsBiotransformationmedia_commonMelaninschemistry.chemical_classificationintegumentary systemPigmentationHair analysisHair folliclemedicine.anatomical_structurePharmaceutical PreparationschemistryBiochemistrysense organsLawBiomarkersHairForensic Science International
researchProduct

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Piroxicam

2014

ABSTRACT Literature and experimental data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate release (IR) solid oral dosage forms containing piroxicam in the free acid form are reviewed. Piroxicam solubility and permeability, its therapeutic use and therapeutic index, pharmacokinetic properties, data related to the possibility of excipient interactions and reported BE/bioavailability (BA), and corresponding dissolution data are taken into consideration. The available data suggest that according to the current biopharmaceutics classification system (BCS) and all current guidances, piroxicam would be assigned to BCS Class II. The ex…

DrugChemistry Pharmaceuticalmedia_common.quotation_subjectBiological AvailabilityPharmaceutical ScienceExcipientBioequivalencePharmacologyPiroxicamDosage formBiopharmaceuticsArthritis RheumatoidExcipientsFood-Drug InteractionsPiroxicamPharmacokineticsmedicineAnimalsHumansTissue Distributionmedia_commonChemistryAnti-Inflammatory Agents Non-SteroidalStereoisomerismBiopharmaceutics Classification SystemRatsBioavailabilityIntestinal AbsorptionSolubilityTherapeutic EquivalencyCaco-2 CellsHalf-Lifemedicine.drugJournal of Pharmaceutical Sciences
researchProduct

Hepatocytes--the choice to investigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo.

2007

The pharmaceutical industry is committed to marketing safer drugs with fewer side effects, predictable pharmacokinetic properties and quantifiable drug-drug interactions. Drug metabolism is a major determinant of drug clearance and interindividual pharmacokinetic differences, and an indirect determinant of the clinical efficacy and toxicity of drugs. Progressive advances in the knowledge of metabolic routes and enzymes responsible for drug biotransformation have contributed to understanding the great metabolic variations existing in human beings. Phenotypic as well genotypic differences in the expression of the enzymes involved in drug metabolism are the main causes of this variability. How…

DrugDiclofenacDrug-Related Side Effects and Adverse Reactionsmedia_common.quotation_subjectBiologyPharmacologyIn Vitro TechniquesToxicologyModels BiologicalPharmacokineticsCytochrome P-450 Enzyme SystemIn vivoGenetic variationHumansDrug InteractionsPharmacokineticsBiotransformationCells Culturedmedia_commonMolecular StructureAnti-Inflammatory Agents Non-SteroidalCytochrome P450Genetic VariationGeneral MedicineIn vitroPharmaceutical PreparationsToxicityInactivation Metabolicbiology.proteinHepatocytesDrug metabolismMetabolic Networks and PathwaysChemico-biological interactions
researchProduct

Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics.

2016

Second-generation antipsychotics (SGAs) are frequently co-prescribed with drug metabolic inducers and inhibitors. SGA pharmacokinetic drug-drug interactions (DDIs) with inducers and inhibitors have not received enough attention in the literature but can be studied in by using therapeutic drug monitoring (TDM).The limited information available on oral SGA pharmacokinetic DDIs is reviewed. A systematic literature search on the available oral SGA TDM studies is completed. By integrating TDM studies with the information on in vitro metabolism studies, case report/series and prospective studies, a table is provided to manage average SGA patients taking inducers or inhibitors by using TDM and/or …

DrugDrug-Related Side Effects and Adverse Reactionsmedia_common.quotation_subjecttherapeutic drug monitoringAdministration OralPharmacologyToxicology030226 pharmacology & pharmacyDrug interactions03 medical and health sciences0302 clinical medicinePharmacokineticsinhibitorsMedicineHumansProspective cohort studyClozapinemedia_commonLurasidoneinducersPharmacologyRisperidonemedicine.diagnostic_testDose-Response Relationship Drugbusiness.industrysecond-generation antipsychoticsGeneral MedicineDrug interactions; inducers; inhibitors; pharmacokinetics; second-generation antipsychotics; therapeutic drug monitoring030227 psychiatryTherapeutic drug monitoringQuetiapineAntidepressive Agents Second-GenerationDrug Monitoringbusinesspharmacokineticsmedicine.drugAntipsychotic Agents
researchProduct

Could the Combined Administration of Bone Antiresorptive Drug, Taxanes, and Corticosteroids Worsen Medication Related Osteonecrosis of the Jaws in Ca…

2018

The study presents a report of 58 metastatic cancer patients who developed osteonecrosis of the jaws after being treated with zoledronic acid and taxanes, plus corticosteroids. A retrospective analysis of data registered in the archives of two Italian osteonecrosis of the jaws treatment centers, who are based at the University of Messina and at the University of Palermo, was performed in order to study, in these patients, demographic data and characteristics such as frequency of cancer location, lines of therapy, frequency of cancer drugs, presence/absence of oral trigger, number, location, and stage of jaw osteonecrosis. It was found that the majority of patients developed advanced stages …

DrugGenetics and Molecular Biology (all)Malemedicine.medical_specialtyExacerbationArticle SubjectImmunology and Microbiology (all)media_common.quotation_subjectlcsh:MedicineClinical manifestationBiochemistryGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineAdrenal Cortex HormonesInternal medicineNeoplasmsmedicineHumansDrug InteractionsStage (cooking)media_commonRetrospective StudiesBiochemistry Genetics and Molecular Biology (all)General Immunology and MicrobiologyBone Density Conservation AgentsDiphosphonatesbusiness.industrylcsh:ROsteonecrosisSoft tissueCancer030206 dentistryGeneral Medicinemedicine.diseaseZoledronic acidBiochemistry Genetics and Molecular Biology (all) Immunology and Microbiology (all)Italy030220 oncology & carcinogenesisBisphosphonate-Associated Osteonecrosis of the JawFemaleTaxoidsbusinessOsteonecrosis of the jawBiochemistry Genetics and Molecular Biology (all); Immunology and Microbiology (all)medicine.drugResearch ArticleBioMed Research International
researchProduct

Predicting the risk of drug–drug interactions in psychiatric hospitals: a retrospective longitudinal pharmacovigilance study

2021

ObjectivesThe aim was to use routine data available at a patient’s admission to the hospital to predict polypharmacy and drug–drug interactions (DDI) and to evaluate the prediction performance with regard to its usefulness to support the efficient management of benefits and risks of drug prescriptions.DesignRetrospective, longitudinal study.SettingWe used data from a large multicentred pharmacovigilance project carried out in eight psychiatric hospitals in Hesse, Germany.ParticipantsInpatient episodes consecutively discharged between 1 October 2017 and 30 September 2018 (year 1) or 1 January 2019 and 31 December 2019 (year 2).Outcome measuresThe proportion of rightly classified hospital epi…

DrugHospitals PsychiatricLongitudinal studymedicine.medical_specialtymedia_common.quotation_subjectHealth informaticslaw.invention03 medical and health sciencesPharmacovigilance0302 clinical medicinelawRisk FactorsGermanyPharmacovigilanceMedicineHumans1723Drug Interactions030212 general & internal medicine1506Longitudinal StudiesMedical prescriptionPsychiatryhealth informaticsmedia_commonRetrospective StudiesPolypharmacyClinical pharmacologyReceiver operating characteristicbusiness.industryRGeneral MedicinePharmacology and Therapeuticspsychiatry030227 psychiatryPharmaceutical PreparationsMedicineclinical pharmacologybusinessBMJ Open
researchProduct

The impact of polypharmacy and drug interactions among the elderly population in Western Sicily, Italy.

2017

Aim: Primary endpoint was to report polypharmacy distribution in the general population vs ≥65 years old people and to examine the frequency of drug–drug interactions (DDIs) in the Health Local Unit of Palermo, Italy, in relationship with patients’ age. Methods: Drug prescription data for the year 2014 were extracted from the database of the Local Health Unit of Palermo Province, Italy. Patients were divided into five age groups (0–13, 14–64, 65–69, 70–74, and ≥75 year old). The detection of potential DDIs in polypharmacy profiles was performed with NavFarma software (Infologic srl, Padova, Italia), with DDI classification provided by tool Micromedex Drug Reax (Truven Health Analitics, Mich…

DrugMaleAgingPediatricsmedicine.medical_specialtyDatabases Factualmedia_common.quotation_subjectDrug interactionPopulationDrug prescription030204 cardiovascular system & hematologySettore MED/42 - Igiene Generale E Applicata03 medical and health sciences0302 clinical medicineDrug Utilization ReviewAge groupsElderly populationInternal medicinemedicineClinical endpointHumansDrug Interactions030212 general & internal medicineSettore SECS-S/05 - Statistica SocialeMedical prescriptioneducationSicilymedia_commonAgedPolypharmacyeducation.field_of_studyElderly populationbusiness.industrySignificant differenceAge FactorsMiddle AgedContraindicated drug-drug interactions.Population SurveillanceChronic DiseaseSettore BIO/14 - FarmacologiaPolypharmacyFemaleGeriatrics and GerontologybusinessAging clinical and experimental research
researchProduct

Polypharmacy and the risk of drug-drug interactions and potentially inappropriate medications in hospital psychiatry.

2021

PURPOSE The aim of this study was to analyze the epidemiology of polypharmacy in hospital psychiatry. Another aim was to investigate predictors of the number of drugs taken and the associated risks of drug-drug interactions and potentially inappropriate medications in the elderly. METHODS Daily prescription data were obtained from a pharmacovigilance project sponsored by the Innovations Funds of the German Federal Joint Committee. RESULTS The study included 47 071 inpatient hospital cases from eight different study centers. The mean number of different drugs during the entire stay was 6.1 (psychotropic drugs = 2.7; others = 3.4). The mean number of drugs per day was 3.8 (psychotropic drugs …

DrugMalemedicine.medical_specialtyEpidemiologymedia_common.quotation_subjectInappropriate Prescribing030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicinePharmacokineticsPharmacovigilanceEpidemiologyMedicineHumansPharmacology (medical)Drug Interactions030212 general & internal medicineRisk factorPsychiatryPotentially Inappropriate Medication Listmedia_commonAgedPolypharmacyPsychiatrybusiness.industryPharmacoepidemiologyHospitalsPsychotropic drugPharmaceutical PreparationsPolypharmacyFemalebusinessPharmacoepidemiology and drug safetyREFERENCES
researchProduct

Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Nifedipine

2015

Literature data relevant to the biopharmaceutical properties of the active pharmaceutical ingredient (API) nifedipine are reviewed to evaluate whether a waiver of in vivo bioequivalence (BE) testing of immediate-release (IR) dosage forms formulated as tablets and soft gelatin capsules is warranted. Nifedipine's solubility and permeability, its therapeutic use and index, pharmacokinetics, food drug interactions, and any reported BE/bioavailability problems were all taken into consideration. Solubility and BA data indicate conclusively that nifedipine is a class II substance of biopharmaceutics classification system (BCS) and that the formulation of drug product plays a key role on the dissol…

DrugNifedipineChemistry Pharmaceuticalmedia_common.quotation_subjectPharmaceutical ScienceCapsulesBioequivalencePharmacologyDosage formExcipientsFood-Drug InteractionsNifedipinePharmacokineticsmedicineAnimalsHumansmedia_commonActive ingredientChemistryCalcium Channel BlockersBiopharmaceutics Classification SystemBioavailabilityIntestinal AbsorptionSolubilityTabletsmedicine.drugJournal of Pharmaceutical Sciences
researchProduct